3-Imino-2-indolones for the treatement of depression and/or anxiety
OwnerMichael Konkel, John M. Wetzel +1inventors
InventorsMichael Konkel, John M. Wetzel, Jamie Talisman
Life of this patent
Estimating the term…
Loading patent…
OwnerMichael Konkel, John M. Wetzel +1inventors
InventorsMichael Konkel, John M. Wetzel, Jamie Talisman
Estimating the term…
This invention is directed to indolone derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.
A compound having the structure:
A compound having the structure:
A compound having the structure:
A compound having the structure:
The method of claim 32, wherein the therapeutically effective amount is between about 0.10 and about 500 mg per day.
The method of claim 33, wherein the therapeutically effective amount is between about 1.0 and about 200 mg per day.
Dependencies are inferred from the claim text.